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SHORT COMMUNICATION
The effect of patterns of oral contraceptive use on breast cancer risk in
young women
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Department ofPublic Health Medicine and Epidemiology, University ofNottingham Medical School; Imperial Cancer Research
Fund Epidemiology Unit, Oxford; Institute ofCancer Research, Sutton, Surrey; Department ofPublic Health and Primary Care,
University ofOxford, UK.
Summary The effect of the duration and pattern of oral contraceptive use on breast cancer risk in young
women (aged under 36 at diagnosis) has been investigated. Oral contraceptive users were divided into three
groups: group 1, continuous users; group 2, interrupted only by pregnancy users; and group 3, intermittent
users. There was a clear trend with duration of oral contraceptive use in all three groups of users (P<0.001
for each category of use) and the relative risks per year of use were similar (1.07, 1.07 and 1.05 in continuous,
interrupted and intermittent users respectively). The relative risks for intermittent users and for women who
had used oral contraceptives except when pregnant were very similar, but the relative risk for users for more
than 8 years was highest for continuous users. The results suggest that the relationship between oral
contraceptive use and breast cancer risk is dependent upon the total duration of use and is not modified by the
pattern of use.
The UK National Case-Control Study was set up to investi-
gate the relationship between oral contraceptive use and
breast cancer risk in young women. We found evidence of a
relationship between oral contraceptive use and breast cancer
risk with a highly significant trend (P<0.001) with duration
of use and relative risks of 1.43 [95% confidence interval (CI)
0.97-2.12] for 49-96 months use and 1.74 (95% CI
1.15-2.62) for 97 or more months use (UKNCCSG, 1989).
There was no evidence of an effect in women who had used
oral contraceptives for less then 4 years, but the data were
compatible with a steady increase in breast cancer risk with
increasing duration of oral contraceptive use. Other studies
of young women have found similar effects (see review by La
Vecchia, 1992) although no increased risk is reported from
studies of older women. A question frequently asked by
doctors involved in family planning is whether these risks are
modified by the pattern of oral contraceptive use, and in
particular whether continuous use is more harmful than
intermittent use.
Materials and methods
The study protocol and the statistical methods used have
been described in detail (UKNCCSG, 1989). Briefly, all
women who were diagnosed as having breast cancer between
1982 and 1985 and who were resident in any of 11 health
regions in the UK were included, provided that their breast
cancer diagnosis was before their 36th birthday. For every
case, one control was chosen, effectively at random, from the
list of that case's general practitioner (GP). The control's
date of birth was matched to within 6 months of the date of
birth of the case, and the control had to have been registered
with the GP before the date ofdiagnosis of the case. If a case
could not be interviewed, no attempt was made to interview
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her matched control. If the chosen control could not be
interviewed a second (or further) control was selected in the
same manner as the first. The study was restricted to white
women with no previous malignancy, severe mental handicap
or psychiatric condition. Each case-control pair was inter-
viewed by the same interviewer. A total of 1049 eligible cases
were identified and 755 (72%) were interviewed. Of the 755
first controls, 675 (89%) were interviewed; the remaining 80
controls were replaced by second (68) or subsequent (12)
choices. At interview contraceptive histories were elicited by
constructing a calendar ofevents for each month from age 14
onwards. Data abstracted from GP notes and family plann-
ing clinics were also used to construct a lifetime contraceptive
calendar.
We defined patterns of oral contraceptive use as follows:
the dates of first and last use of oral contraceptives were
known for each woman; if use had been uninterrupted
between those dates except for a maximum of 2 months off
oral contraceptives, use was defined as continuous (31
women had a gap of 1 month and 34 a gap of 2 months); if
use was interrupted only by one or more pregnancies and the
interruption of oral contraceptive use for each pregnancy was
the time actually pregnant plus not more than a total of 6
months (for example 3 months before becoming pregnant
and 3 months after delivery), then use was defined as 'inter-
rupted only by pregnancy'; all other use was defined as
'intermittent'.
Results
The numbers of cases and controls in the three subgroups of
use with relative risks (RR) and 95% confidence intervals are
shown in Table I. Among the intermittent users 71% (232/
327) of cases and 69% (221/319) of controls had used oral
contraceptives for more than 50% of the interval between
first starting and either finally stopping oral contraceptive use
or the date of diagnosis/pseudodiagnosis. The table shows a
clear trend with duration of oral contraceptive use in all
three categories of use (P<0.001 for each category of use).
The test for heterogeneity of trends in relative risks was not
statistically significant (X22 = 1.16, P = 0.56). The relative risk
for the longest duration of use category (97 months or more)
was highest in continuous users (RR = 2.57, RR = 1.65 and
RR = 1.53 for continuous, interrupted and intermittent users
respectively), but this difference was not statistically
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Table I Relative risk of breast cancer by duration and pattern of use of oral
contraceptives
Type of Duration of Number of RR
use use (montths) Cases Controls (95% CI)
Never 0 67 80 1.00
Continuousb 1-48 91 134 0.86 (0.55, 1.33)
49-96 49 44 1.25 (0.72, 2.16)
97+ 38 18 2.57 (1.31, 5.05)
Per year of use 1.07 (1.02, 1.12)
Interrupted only 1-48 35 41 1.07 (0.59, 1.94)
by pregnancyc 49-96 82 65 1.70 (1.04, 2.79)
97 + 66 54 1.65 (0.99, 2.78)
Per year of use 1.07 (1.03, 1.11)
Intermittentd 1-48 92 110 1.00 (0.63, 1.58)
49-96 141 138 1.34 (0.87, 2.06)
97 + 94 71 1.53 (0.95, 2.45)
Per year of use 1.05 (1.02, 1.09)
aAdjusted for age at menarche, nulliparity, age at first full-term pregnancy, breastfeeding
(ever, never), family history of breast cancer (mother or sister). Test for heterogeneity of trends
in relative risk by duration ofuse for different types ofuse: X22 = 1.16, P = 0.56. bTest for trend
among continuous users: XI2 = 12.19, P <0.001; cTest for trend among interrupted users:
XI2 = 11.92, P <0.001; dTest for trend among intermittent users: X12 = 10.70, P <0.001 (tests
for trend use actual months of use).
significant. The relative risks per year of use were, however,
similar in the three groups (1.07, 1.07 and 1.05 in continuous,
interrupted and intermittent users respectively). An analysis
allowing no breaks in use for uninterrupted users was also
carried out and gave almost identical results.
Discussion
The relative risks per year of use in the three groups were
very similar, and the test for heterogeneity showed no
evidence of a difference in risk. Thus, although the relative
risk for continuous oral contraceptive use for more than 8
years is higher than for the other two groups, this difference
may well be due to chance. The relative risks for intermittent
long-term use or long-term use interrupted only by preg-
nancy are very similar. These data thus provide little evidence
that the relationship between total duration of oral contra-
ceptive use and breast cancer risk found in the UK National
Study (UKNCCSG, 1989) is modified by the pattern of use.
It is important to note that the UK National Study results
were confined to women diagnosed with breast cancer when
very young (less than 36 years) and that most of these
women had begun to use oral contraceptives before the age
of 25. Most long-term oral contraceptive use was of the older
high-dose pills, and we have previously reported some
evidence that the modern lower dose pills may be less harm-
ful (UKNCCSG, 1989). Subgroup analyses which investi-
gated possible high-risk groups (UKNCCSG, 1990) indicated
no sub-group with a statistically significant modification of
oral contraceptive-associated breast cancer risk. Attention
was, however, drawn to the higher risks in women with a
family history of breast cancer in a first-degree relative, and
to the likelihood that the effects of oral contraceptive use and
of having such a family history are multiplicative. In the
absence of any substantial evidence that interruption of oral
contraceptive use diminishes the increased risk of breast
cancer in young women found in long-term oral contracep-
tive users (La Vecchia, 1992), the timing of oral contraceptive
use should be determined primarily by the need for maximal
contraceptive efficacy, which for most women is likely to be
before the first pregnancy.
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